Q: hi guys could you please give me your opinion on this company and whether it has any legs .there was a ton of insider selling but they have given it a 23 dollar target at td .THANKS AS ALWAYS
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
-
Intuitive Surgical Inc. (ISRG $518.62)
-
AbbVie Inc. (ABBV $189.26)
-
Gamehost Inc. (GH $12.38)
-
iShares Biotechnology ETF (IBB $129.73)
-
SPDR Biotech ETF (XBI $86.27)
Q: can you recommend a Canadian and Us biotech etf and stock?
thanks
thanks
Q: Hello,
No questions on TRIL for 6 months now. Stock is moving higher again. Any thoughts on its potential now, and risks?
Thanks for your insight.
No questions on TRIL for 6 months now. Stock is moving higher again. Any thoughts on its potential now, and risks?
Thanks for your insight.
Q: I have a 1 per cent position in ABCL. Do you think the insider selling is over ?
Is the stock a buy, sell or hold ? I plan on holding this stock for the long term.
Thanks for this great service.
Is the stock a buy, sell or hold ? I plan on holding this stock for the long term.
Thanks for this great service.
Q: Hi guys
Had a pleasant surprise today, for a change, a company that I had written off, started trading today after a long halt, change of business, it is trading at $ ,70 or so, my cost base is $.35, can you tell me something about this one, how does the future look, should I blow it out, or hold on, in your opinion.
thanks for your time and keep safe
Auftar
Had a pleasant surprise today, for a change, a company that I had written off, started trading today after a long halt, change of business, it is trading at $ ,70 or so, my cost base is $.35, can you tell me something about this one, how does the future look, should I blow it out, or hold on, in your opinion.
thanks for your time and keep safe
Auftar
Q: Could you provide any up- dated assessment you may have re. Novo Nordisk in light of FDA approval of their obesity drug Wegovy. The monthly cost of a regimen of the drug is apparently $800.00 ( without insurance ) . But with 100 million obese Americans and obesity increasing risk factors for many other diseases, might it be a reasonable speculation that insurers may cover the drug at some point. Any sense of how much of this potential might be already factored in and how much might be a potential game changer if it plays out successfully over time?
Thank-you
Thank-you
Q: Your views on AMGN. The price is moving in the range between US$230 to US$245. Pays a dividend yielding 2.5% plus and increasing dividend year over year. One bad thing is happening with its new drugs. They are failing and not getting approval. Your views. Should exit the position? What's your choice? Do not own any drug company but own BAX-N as 10% of my portfolio. I run very concentrated portfolio based on individual companies and ignoring sectors.
Q: with a small position does this company look ok for a buy?
Q: i am up 33% on small position with Microbix.
What does next few years look like for more upside?
What does next few years look like for more upside?
Q: I research info south of the border and have found some small momentum stocks: HITI-CA (High Tide), MILE-Q (Metromile - insurance business), CERC-Q (Cerecor - medical) which the CEO and Senior Officers are from Celgenc and these stocks are fast moving to the upside. Your opinion? I checked and none of them can be found in your search engine. Thanks again.
Q: HI Gang
I have a happy problem....BNTX is growing exponentially. I sold some of my shares one month ago and cannot decide whether I should shave a few more off. My weighting is 2.85% again. (But I have 65 stocks - still trying to reduce this). If I were to own only 25 or so stocks my weighting would be over 8%. How should I think of proceeding?
Thank you and stay safe...we are hopefully closing in on the finish line.
I have a happy problem....BNTX is growing exponentially. I sold some of my shares one month ago and cannot decide whether I should shave a few more off. My weighting is 2.85% again. (But I have 65 stocks - still trying to reduce this). If I were to own only 25 or so stocks my weighting would be over 8%. How should I think of proceeding?
Thank you and stay safe...we are hopefully closing in on the finish line.
Q: Merging with SBBP, huge short, waking up. Hold or Sell ? Your assessment. Thanks
Q: What are your thoughts on Well’s acquisition this morning? Also, can you please explain the financing? They mention the 9.80 stock and vendor take back.
Thanks.
Thanks.
Q: Please provide thoughts and commentary on today's acquisition announcement.
Thanks
Thanks
Q: What are your thoughts on WELL presently? I've read that WELL is looking be dual listing on the TSX and NASDAQ, what will that do for the stock value?
Thank you
Thank you
Q: Good Day Great Service,What do you think will have the best growth in yet next 4 to 5 years. Thanks
-
AbbVie Inc. (ABBV $189.26)
-
Stryker Corporation (SYK $389.40)
-
Veeva Systems Inc. Class A (VEEV $282.29)
-
Guardant Health Inc. (GH $46.46)
Q: I am looking to increase my healthcare exposure in the US. Would you recommend VEEV or GH or both or would you have other recommendations. Risk is not a factor.
Thanks for your service!
Thanks for your service!
Q: Hi Peter, I've taken some comfort despite my loss on BDX shares because some commentators have pointed out that their products (joint replacements) will soon benefit from the pent-up demand due to Covid-caused delays in such surgeries. However, Stryker, which is in a similar business, has significantly outperformed BDX both before and after Covid. In other words, do you know why BDX is so underperforming SYK, and would you hang onto (or perhaps add to) BDX at this point? Thank you.
Q: Regarding todays nr, is it safe to assume the observations from the clinical trial are in a positive light? I have a small position and am considering adding - since the casino is closed. London, Ontario-TheNewswire -June 1, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead principal investigator Dr. Piotr Witkowski and the Clinical Trial Investigator Team for its US Phase I/II Type 1 Diabetes clinical trial will present data and observations from the ongoing study in a presentation at the upcoming American Transplant Congress (ATC) Virtual Connect to be held June 4 - 9, 2021.
Q: your opinion on buying this stock at today's price and future growth ..thx